{
    "id": 2771,
    "fullName": "BRAF L505H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BRAF L505H lies within the protein kinase domain of the Braf protein (UniProt.org). L505H confers a gain of function to the Braf protein resulting in MEK/ERK activation and oncogenic transformation in cultured cells, and is associated with resistance to RAF inhibitors (PMID: 24283590).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1371,
                    "pubMedId": 24283590,
                    "title": "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24283590"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "L505H",
    "createDate": "12/18/2014",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 109222,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140777994A>T",
        "cDna": "c.1514T>A",
        "protein": "p.L505H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590).",
            "molecularProfile": {
                "id": 2594,
                "profileName": "BRAF L505H"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1371,
                    "pubMedId": 24283590,
                    "title": "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24283590"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600E treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",
            "molecularProfile": {
                "id": 13538,
                "profileName": "BRAF L505H BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3825,
                    "pubMedId": 25515853,
                    "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25515853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2594,
            "profileName": "BRAF L505H",
            "profileTreatmentApproaches": [
                {
                    "id": 14417,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14418,
                    "name": "LY3009120",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14416,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF L505H"
                },
                {
                    "id": 14415,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF L505H"
                }
            ]
        },
        {
            "id": 13538,
            "profileName": "BRAF L505H BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 109222,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140777994A>T",
            "cDna": "c.1514T>A",
            "protein": "p.L505H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 109221,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140777994A>T",
            "cDna": "c.1514T>A",
            "protein": "p.L505H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}